Optimal protamine-to-heparin dosing ratio for the prevention of bleeding complications in patients undergoing TAVR-A multicenter experience.
Clinical cardiology
View this publicationClinical cardiology
View this publicationNature communications
View this publicationFrontiers in immunology
View this publicationeLife
View this publicationHeart and vessels
View this publicationNature reviews. Nephrology
View this publicationCell surface (Amsterdam, Netherlands)
View this publicationCancer research
View this publicationInternational journal of cancer
View this publicationBioinformatics (Oxford, England)
View this publication